Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Afamelanotide, Photo-Protective Drug

Drug

Afamelanotide

Company

Clinuvel Pharmaceuticals

Therapy Class

Photoprotective drugs

Product Description

Prophylactic treatment for skin disorders

Current Indication

Erythropoietic protoporphyria, photodynamic therapy, solar urticaria, actinic keratosis / squamous cell carcinoma and polymorphous light eruption

Market Sector

Dermatology

Development Status

Phase III confirmatory study under progress, received ODD status from the FDA and EMEA, granted IND status by the FDA
Expand

Go Top